Combining DNMT and HDAC inhibitors with other targeted therapies like EZH2 inhibitors can synergistically restore normal gene function and inhibit tumor growth by reactivating tumor‐suppressor genes and modulating signaling pathways. This evidence concerns the gene HDAC9 and neoplasm.